Sciencast Management LP Invests $1.39 Million in Pfizer Inc. (NYSE:PFE)

Sciencast Management LP acquired a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 52,277 shares of the biopharmaceutical company's stock, valued at approximately $1,387,000.

Other institutional investors also recently bought and sold shares of the company. Swedbank AB raised its stake in shares of Pfizer by 0.7% in the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company's stock valued at $166,284,000 after acquiring an additional 37,636 shares in the last quarter. United Bank raised its position in Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company's stock valued at $1,030,000 after purchasing an additional 1,277 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new position in shares of Pfizer in the 3rd quarter valued at about $2,123,000. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Pfizer by 67.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,801 shares of the biopharmaceutical company's stock worth $428,000 after buying an additional 5,959 shares in the last quarter. Finally, Pacer Advisors Inc. increased its stake in shares of Pfizer by 5.1% during the third quarter. Pacer Advisors Inc. now owns 431,232 shares of the biopharmaceutical company's stock worth $12,480,000 after buying an additional 20,769 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock bought 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.06% of the company's stock.

Remove Ads

Pfizer Stock Performance

NYSE:PFE traded down $0.35 during mid-day trading on Tuesday, reaching $25.80. The stock had a trading volume of 13,002,162 shares, compared to its average volume of 36,645,983. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business has a 50 day simple moving average of $26.15 and a 200 day simple moving average of $27.02. The firm has a market capitalization of $146.30 billion, a price-to-earnings ratio of 18.29, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter last year, the business earned $0.10 earnings per share. The business's revenue for the quarter was up 24.7% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on PFE shares. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Bank of America reaffirmed a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.